PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase InhibitorsMichael E. Stokes, David Surguladze, Mark J. Mulvihill et al.|Clinical Cancer Research|2023Cited by 27
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase ActivatorChristopher G. Thomson, Savithri Ramurthy, Thomas D. Aicher et al.|Journal of Medicinal Chemistry|2024Cited by 16
A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.Arkadiusz Z. Dudek, J. L. Mesías Iglesias, Joyce O’Shaughnessy et al.|Journal of Clinical Oncology|2024Cited by 13
1327 Novel GCN2 modulator HC-7366 decreases pulmonary metastases and reduces myeloid-derived suppressor cellsJeremy Drees, Nandita Bose, Anissa Chan et al.|Regular and Young Investigator Award Abstracts|2022Cited by 5
Abstract 6231: Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer modelsFeven Tameire, Nandita Bose, Paulina M. Wojnarowicz et al.|Cancer Research|2023Cited by 3